VRTX 250509 497.50C(VRTX250509C497500) Stock Price Today | Quotes & News - Moomoo

US OptionsDetailed Quotes

VRTX250509C497500

Watchlist

14.95
-3.06-16.99%

15min DelayClose May 2 16:00 ET

14.95High14.20Low

Intraday

5D
Daily

News

Vertex Pharmaceuticals Q1 2025 Earnings Preview
Seeking Alpha17:35 ET
Notable Healthcare Headlines for the Week: Gilead, CVS Health, Sanofi in Focus
Seeking Alpha14:53 ET
Earnings Week Ahead: AMD, PLTR, F, DIS, SHOP, DKNG, AMC, LCID, GOLD, RIVN, and More
Seeking AlphaMay 4 08:00 ET
Healthcare Sector Flexes Earnings Muscle, but Top-line Cracks Show
Seeking AlphaMay 3 18:10 ET
Gilead and Vertex Pharma Named Among Biotech's Tariff Safe Havens
Seeking AlphaMay 3 14:09 ET
Preview -- Barron's
Barron'sMay 2 21:30 ET

Comments

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

$Vertex Pharmaceuticals (VRTX.US)$
Revolutionary CF Treatment Pioneer at Vertex Receives Top Medical Honor: How It Transforms Patient Care

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis

$Vertex Pharmaceuticals (VRTX.US)$
Major EU Victory: KAFTRIO Now Approved for 4,000 More CF Patients, Including Children

European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

$Vertex Pharmaceuticals (VRTX.US)$
Revolutionary Gene Therapy CASGEVY Now Available Through NHS England: Major Win for Sickle Cell Patients

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

1

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

$Vertex Pharmaceuticals (VRTX.US)$
FDA Approves First Non-Opioid Pain Drug in 20 Years: Vertex's Game-Changing Alternative to Opioids

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

1

$Vertex Pharmaceuticals (VRTX.US)$

Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller

1

Read more